Aadi Biosciences News

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings

BenzingaMay 9 20:06

Aadi Bioscience Inc (AADI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...

Yahoo FinanceMay 9 15:11

Aadi Biosciences | 10-Q: Quarterly report

Futu NewsMay 9 04:10 · Announcements

Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.4M

08:07 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (AADI) AADI BIOSCIENCE Reports Q1 Revenue $5.4M

MT NewswiresMay 8 20:07

Aadi Bioscience: Runway To Fund Operations Into 4Q 2025 >AADI

Aadi Bioscience: Runway To Fund Operations Into 4Q 2025 >AADI

Dow JonesMay 8 20:03

Aadi Bioscience Q1 2024 GAAP EPS $(0.68) Misses $(0.65) Estimate, Sales $5.353M Miss $6.454M Estimate

Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. The company reported quarterly sales of $5.353 mil

BenzingaMay 8 20:02

Aadi Bioscience: Expect to Return to Sales Growth in 2Q >AADI

Aadi Bioscience: Expect to Return to Sales Growth in 2Q >AADI

Dow JonesMay 8 20:02

Aadi Bioscience 1Q Loss $18.3M >AADI

Aadi Bioscience 1Q Loss $18.3M >AADI

Dow JonesMay 8 20:01

Aadi Bioscience 1Q Loss/Shr 68c >AADI

Aadi Bioscience 1Q Loss/Shr 68c >AADI

Dow JonesMay 8 20:01

Aadi Bioscience 1Q Rev $5.35M >AADI

Aadi Bioscience 1Q Rev $5.35M >AADI

Dow JonesMay 8 20:01

Press Release: Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update

LOS ANGELES, May 8, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Dow JonesMay 8 20:01

Aadi Biosciences(AADI.US) Officer Sells US$77,184 in Common Stock

$Aadi Biosciences(AADI.US)$ Officer Desai Neil sold 40,000 shares of common stock on May 1, 2024 at an average price of $1.9296 for a total value of $77,184.Source: Announcement What is statement of c

Futu NewsMay 2 09:31

Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...

PR NewswireMay 1 20:01

Aadi Bioscience, Inc. (NASDAQ:AADI) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Aadi Bioscience, Inc. (NASDAQ:AADI) shares have retraced a considerable 25% in the last month, reversing a fair amount of their solid recent performance. For any long-term shareholders, the last mo

Simply Wall StApr 28 22:07

Aadi Biosciences(AADI.US) Officer Sells US$90,614.17 in Common Stock

$Aadi Biosciences(AADI.US)$ Officer Desai Neil sold 40,000 shares of Common Stock on Apr 1, 2, 2024 at an average price of $2.2654 for a total value of $90,614.17.Source: Announcement What is statemen

Futu NewsApr 4 05:33

Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology

Subgroup experienced efficacy and safety consistent with overall study populationAdvanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled

BenzingaMar 18 14:24

Aadi Bioscience Presents New Subgroup Analysis of Patients With Advanced Malignant PEComa of Gynecologic Origin Treated With Nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...

PR NewswireMar 17 20:00

Earnings Call Summary | Aadi Biosciences(AADI.US) Q4 2023 Earnings Conference

The following is a summary of the Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript:Financial Performance:Aadi Bioscience reported impressive sales growth with full-year sales for FYARRO h

Futu NewsMar 14 00:13 · Conference Call

Aadi Bioscience Cash Runway Extends to 4Q 2025 >AADI

Aadi Bioscience Cash Runway Extends to 4Q 2025 >AADI

Dow JonesMar 13 20:04

Aadi Bioscience's Cash, Cash Equivalents And Short-term Investments As Of December 31, 2023, Is Expected To Fund Operations Into Q4 2025 Based On Current Plans

Aadi Bioscience's Cash, Cash Equivalents And Short-term Investments As Of December 31, 2023, Is Expected To Fund Operations Into Q4 2025 Based On Current Plans

BenzingaMar 13 20:03